Placebos without Deception: A Randomized Controlled Trial in Irritable Bowel Syndrome
Open accessThe DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Placebo treatment can significantly influence subjective symptoms. However, it is widely believed that response to placebo requires concealment or deception. We tested whether open-label placebo (non-deceptive and non-concealed administration) is superior to a no-treatment control with matched patient-provider interactions in the treatment of irritable bowel syndrome (IBS). METHODS: Two-group, randomized, controlled three week trial (August 2009-April 2010) conducted at a single academic center, involving 80 primarily female (70%) patients, mean age 47 ± 18 with IBS diagnosed by Rome III criteria and with a score ≥ 150 on the IBS Symptom Severity Scale (IBS-SSS). Patients were randomized to either open-label placebo pills presented as "placebo pills made of an inert substance, like sugar pills, that have been shown in clinical studies to produce significant improvement in IBS symptoms through mind-body self-healing processes" or no-treatment controls with the same quality of interaction with providers. The primary outcome was IBS Global Improvement Scale (IBS-GIS). Secondary measures were IBS Symptom Severity Scale (IBS-SSS), IBS Adequate Relief (IBS-AR) and IBS Quality of Life (IBS-QoL). FINDINGS: Open-label placebo produced significantly higher mean (±SD) global improvement scores (IBS-GIS) at both 11-day midpoint (5.2 ± 1.0 vs. 4.0 ± 1.1, p<.001) and at 21-day endpoint (5.0 ± 1.5 vs. 3.9 ± 1.3, p = .002). Significant results were also observed at both time points for reduced symptom severity (IBS-SSS, p = .008 and p = .03) and adequate relief (IBS-AR, p = .02 and p = .03); and a trend favoring open-label placebo was observed for quality of life (IBS-QoL) at the 21-day endpoint (p = .08). CONCLUSION: Placebos administered without deception may be an effective treatment for IBS. Further research is warranted in IBS, and perhaps other conditions, to elucidate whether physicians can benefit patients using placebos consistent with informed consent. TRIAL REGISTRATION: ClinicalTrials.gov NCT01010191.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The number-needed-to-treat was 11 which should be compared with 4 for ‘placebo without deception,259 7 for alosetron,260 8 for linaclotide261 and 14 for tegaserod.262”
From Intestinal microbiota in functional bowel disorders: a Rome foundation report (2013) · cites this paper as [259]
The cited source says what the claim attributes to it.
In the citing paper
“Several trials of psychological treatments for IBS have failed to show differential effects on symptoms when using attention control conditions [32,62-64], and a recent study showed that IBS patients even respond to open-label placebo [65].”
The cited source says what the claim attributes to it.
In the citing paper
“Kaptchuk and colleagues showed that an open label inactive placebo pill produced better outcomes in IBS patients compared to no treatment13.”
From Is ginger effective for the treatment of irritable bowel syndrome? A double blind randomized controlled pilot trial (2014) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Discovery of Grounded Theory; Strategies for Qualitative Research
Glaser, B. G., Strauss, A. L., & Strutzel, E. (1968) · Nursing Research · doi:10.1097/00006199-196807000-00014 · Cited by 39,449
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,335
Cohen, J. (1992) · Psychological Bulletin · doi:10.1037//0033-2909.112.1.155 · Cited by 8,771
Collecting and Interpreting Qualitative Materials
Denzin, N. K., & Lincoln, Y. S. (2012) · Cited by 6,094
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
Functional bowel disorders and functional abdominal pain
Thompson, W. G., Longstreth, G. F., Drossman, D. A., Heaton, K. W., Irvine, E. J., & Müller-Lissner, S. A. (1999) · Gut · doi:10.1136/gut.45.2008.ii43 · Cited by 2,440 · cited 1×
“Participants were adults ($18 years old) meeting the Rome III criteria for IBS [17] with a score of $150 on the IBS Symptom Severity Scale (IBS-SSS).”
MethodFRANCIS, C. Y., MORRIS, J., & WHORWELL, P. J. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.142318000.x · Cited by 1,708 · cited 3×
“[18] The open-label group improved by 92 points on this measure; in addition, the improvement shown by the openlabel placebo group exceeded that shown by the no-treatment group by 46 points.”
MethodInfluentialIs the Placebo Powerless?: An Analysis of Clinical Trials Comparing Placebo with No Treatment
Hróbjartsson, A., & Gøtzsche, P. C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105243442106 · Cited by 1,503
AGA technical review on irritable bowel syndrome.
Drossman, D. A., Camilleri, M., Mayer, E. A., & Whitehead, W. E. (2002) · Gastroenterology · doi:10.1053/gast.2002.37095 · Cited by 1,384 · cited 1×
“[7,8] It is a chronic functional gastrointestinal disorder characterized by abdominal pain and discomfort associated with altered bowel habits.”
BackgroundBiological, clinical, and ethical advances of placebo effects
Finniss, D. G., Kaptchuk, T. J., Miller, F., & Benedetti, F. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61706-2 · Cited by 1,272
Self-citation
Research works printed but not linked: 1
- Vanner SJ Depew WT Paterson WG 2004 Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome and functional dyspepsia. Gut 53 666 72 · DOI · Paper page
Cited by
RELIEVING PAIN IN AMERICA: A BLUEPRINT FOR TRANSFORMING PREVENTION, CARE, EDUCATION, AND RESEARCH
Simon, L. S. (2012) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.3109/15360288.2012.678473 · Cited by 2,183
Intestinal microbiota in functional bowel disorders: a Rome foundation report
Simrén, M., Barbara, G., Flint, H. J., Spiegel, B. M. R., Spiller, R. C., Vanner, S., Verdu, E. F., Whorwell, P. J., & Zoetendal, E. G. (2013) · Gut · doi:10.1136/gutjnl-2012-302167 · Cited by 939
The neuroscience of placebo effects: connecting context, learning and health
Wager, T. D., & Atlas, L. Y. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3976 · Cited by 844
The placebo response in medicine: minimize, maximize or personalize?
Enck, P., Bingel, U., Schedlowski, M., & Rief, W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3923 · Cited by 671
(2020) · doi:10.1056/nejmra1907805 · Cited by 634
Wise interventions: Psychological remedies for social and personal problems.
Walton, G. M., & Wilson, T. D. (2018) · Psychological Review · doi:10.1037/rev0000115 · Cited by 617
Ford, A. C., Lacy, B. E., & Talley, N. J. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1607547 · Cited by 587
Implications of placebo and nocebo effects for clinical practice: Expert consensus
Evers, A. W. M., Colloca, L., Blease, C., Annoni, M., Atlas, L. Y., Benedetti, F., Bingel, U., Büchel, C., Carvalho, C., Colagiuri, B., et al. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000490354 · Cited by 562
Self-citationPlacebo Analgesia: A Predictive Coding Perspective
Büchel, C., Geuter, S., Sprenger, C., & Eippert, F. (2014) · Neuron · doi:10.1016/j.neuron.2014.02.042 · Cited by 505
“In some studies, the authors have demonstrated placebo effects when telling participants explicitly that they will receive a placebo (Kaptchuk et al., 2010).”
Talley, N. J., & Ford, A. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1501505 · Cited by 424
Open-label placebo treatment in chronic low back pain: a randomized controlled trial
Carvalho, C., Caetano, J. M., Cunha, L., Rebouta, P., Kaptchuk, T. J., & Kirsch, I. (2016) · Pain · doi:10.1097/j.pain.0000000000000700 · Cited by 419
“Our study supports earlier studies that suggest a benefit for OLP treatment.(17,19,25,28)”
BackgroundResultSelf-citationAltered Placebo and Drug Labeling Changes the Outcome of Episodic Migraine Attacks
Kam-Hansen, S., Jakubowski, M., Kelley, J. M., Kirsch, I., Hoaglin, D. C., Kaptchuk, T. J., & Burstein, R. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3006175 · Cited by 399
“A therapeutic benefit of open-label placebo versus no treatment was also recently reported for patients with irritable bowel syndrome in a randomized controlled study (8) and in a pilot study in depression (9).”
BackgroundSelf-citationZeidan, F., Emerson, N. M., Farris, S. R., Ray, J. N., Jung, Y., McHaffie, J. G., & Coghill, R. C. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.2542-15.2015 · Cited by 369
Freedland, K. E., Mohr, D. C., Davidson, K. W., & Schwartz, J. E. (2011) · Psychosomatic Medicine · doi:10.1097/psy.0b013e318218e1fb · Cited by 369
“This is evident, for example, in the highly variable placebo response rates that dozens of antidepressant trials have yielded among patients with major depression (101), in controversies that have arisen concerning the magnitude of placebo effects in many other trials (123Y127), and in the surprising efficacy of ‘‘ope…”
BackgroundVan Strydonck, D. A. C., Slot, D. E., Van der Velden, U., & Van der Weijden, F. (2012) · Journal of Clinical Periodontology · doi:10.1111/j.1600-051x.2012.01883.x · Cited by 353
Ashar, Y. K., Gordon, A., Schubiner, H., Uipi, C., Knight, K., Anderson, Z., Carlisle, J., Polisky, L., Geuter, S., Flood, T. F., et al. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.2669 · Cited by 331
Schedlowski, M., Enck, P., Rief, W., & Bingel, U. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009423 · Cited by 323
“, 2008a) and in which an open-label placebo produced significantly higher global-improvement scores in these patients (Kaptchuk et al., 2010).”
BackgroundPetrie, K. J., & Rief, W. (2019) · Annual Review of Psychology · doi:10.1146/annurev-psych-010418-102907 · Cited by 309
Leigh, H. (2015) · Handbook of Consultation-Liaison Psychiatry · doi:10.1007/978-3-319-11005-9_14 · Cited by 309
Facing depression with botulinum toxin: A randomized controlled trial
Wollmer, M. A., de Boer, C., Kalak, N., Beck, J., Götz, T., Schmidt, T., Hodzic, M., Bayer, U., Kollmann, T., Kollewe, K., et al. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.01.027 · Cited by 278
“However, high unblinding rates are common in antidepressant trials and a recent study shows that open-label placebo treatment can still induce clinical improvement (Perlis et al., 2010; Even et al., 2000; Kaptchuk et al., 2010).”
BackgroundThe Placebo Effect in Pain Therapies
Colloca, L. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021542 · Cited by 270
Genetics and the placebo effect: the placebome
Hall, K. T., Loscalzo, J., & Kaptchuk, T. J. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.02.009 · Cited by 266
Self-citationThe placebo effect: From concepts to genes
Colagiuri, B., Schenk, L. A., Kessler, M. D., Dorsey, S. G., & Colloca, L. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.08.017 · Cited by 258
“Why else would patients expect improvement? A handful of open-label placebo studies where patients know a placebo is being administered challenge that conception (Park and Covi, 1965; Sandler and Bodfish, 2008; Kaptchuk et al., 2010; Kelley et al., 2012).”
Improving Methodological Standards in Behavioral Interventions for Cognitive Enhancement
Shawn Green, C., Bavelier, D., Kramer, A. F., Vinogradov, S., Ansorge, U., Ball, K. K., Bingel, U., Chein, J. M., Colzato, L. S., Edwards, J. D., et al. (2019) · Journal of Cognitive Enhancement · doi:10.1007/s41465-018-0115-y · Cited by 235
“…told that they are taking a placebo—and yet the benefits typically associated with placebos are nonetheless still observed, particularly when a prior conditioning mechanism is already in place (Carvalho et al. 2016; Kaptchuk et al. 2010; Kelley et al. 2012; Sandler and Bodfish 2008).”
BackgroundGoldman, R. L., Borckardt, J. J., Frohman, H. A., O’Neil, P. M., Madan, A., Campbell, L. K., Budak, A., & George, M. S. (2011) · Appetite · doi:10.1016/j.appet.2011.02.013 · Cited by 228
Symptom perception, placebo effects, and the Bayesian brain
Ongaro, G., & Kaptchuk, T. J. (2019) · Pain · doi:10.1097/j.pain.0000000000001367 · Cited by 208
“This evidence is fully compatible with the finding that patients can receive benefit in an “open-label placebo” paradigm, in which they are honestly told that they are receiving a placebo.(8,24,26) From a predictive processing perspective, some of this response is probably triggered because of unconscious predictions…”
ResultSelf-citationPlacebos in chronic pain: evidence, theory, ethics, and use in clinical practice
Kaptchuk, T. J., Hemond, C. C., & Miller, F. G. (2020) · BMJ · doi:10.1136/bmj.m1668 · Cited by 206
Self-citationCharlesworth, J. E. G., Petkovic, G., Kelley, J. M., Hunter, M., Onakpoya, I., Roberts, N., Miller, F. G., & Howick, J. (2017) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12251 · Cited by 199
“The conditions treated in these trials were: depression,(16) attention deficit hyperactivity disorder (ADHD),(14) irritable bowel syndrome (IBS), (12) allergic rhinitis, (32) and chronic lower back pain.”
BackgroundMethodInfluentialSelf-citationBrain Mechanisms of the Placebo Effect: An Affective Appraisal Account
Ashar, Y. K., Chang, L. J., & Wager, T. D. (2017) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-021815-093015 · Cited by 191
Open-Label Placebo for Major Depressive Disorder: A Pilot Randomized Controlled Trial
Kelley, J. M., Kaptchuk, T. J., Cusin, C., Lipkin, S., & Fava, M. (2012) · Psychotherapy and Psychosomatics · doi:10.1159/000337053 · Cited by 190
Self-citationLocher, C., Frey Nascimento, A., Kirsch, I., Kossowsky, J., Meyer, A., & Gaab, J. (2017) · Pain · doi:10.1097/j.pain.0000000000001012 · Cited by 188
Self-citationPlacebo Use in the United Kingdom: Results from a National Survey of Primary Care Practitioners
Howick, J., Bishop, F. L., Heneghan, C., Wolstenholme, J., Stevens, S., Hobbs, F. D. R., & Lewith, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058247 · Cited by 180
Placebo effects in children: a review
Weimer, K., Gulewitsch, M. D., Schlarb, A. A., Schwille-Kiuntke, J., Klosterhalfen, S., & Enck, P. (2013) · Pediatric Research · doi:10.1038/pr.2013.66 · Cited by 178
Effects of open-label placebos in clinical trials: a systematic review and meta-analysis
von Wernsdorff, M., Loef, M., Tuschen-Caffier, B., & Schmidt, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-83148-6 · Cited by 177
Singh, D., Jones, P. W., Bateman, E. D., Korn, S., Serra, C., Molins, E., Caracta, C., Gil, E. G., & Leselbaum, A. (2014) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-14-178 · Cited by 176
“A ‘Hawthorne effect’ often occurs in COPD trials whereby patients treated with placebo improve by participating in a clinical study [27], particularly in countries where healthcare is not free or easily accessible.”
BackgroundHafliðadóttir, S. H., Juhl, C. B., Nielsen, S. M., Henriksen, M., Harris, I. A., Bliddal, H., & Christensen, R. (2021) · Trials · doi:10.1186/s13063-021-05454-8 · Cited by 173
Placebo effects and their determinants in gastrointestinal disorders
Elsenbruch, S., & Enck, P. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.117 · Cited by 173
Oeberst, A., & Imhoff, R. (2023) · Perspectives on Psychological Science · doi:10.1177/17456916221148147 · Cited by 168
“…that either have no (immediate and thus likely detectable) detrimental consequences or even lead to positive consequences (for placebo effects, see Kaptchuk et al., 2010; Kennedy & Taddonio, 1976; Price et al., 2008; for magical thinking, see Subbotsky, 2004; for belief in a just world, see…”
BackgroundManchikanti, L. (2015) · Pain Physician · doi:10.36076/ppj.2015/18/e535 · Cited by 171
Antidepressants and the placebo effect
Kirsch, I. (2014) · Zeitschrift für Psychologie · doi:10.1027/2151-2604/a000176 · Cited by 164
“My colleagues and I have tested and confirmed the hypothesis that placebos can be effective even when given openly, without deception, when given in the context of a warm therapeutic relationship and with an honest but convincing rationale as to why they should be effective (Kaptchuk et al., 2010).”
BackgroundResultSelf-citationThe placebo and nocebo effect on sports performance: a systematic review
Hurst, P., Schipof‐Godart, L., Szabo, A., Raglin, J., Hettinga, F., Roelands, B., Lane, A., Foad, A., Coleman, D., & Beedie, C. (2020) · European Journal of Sport Science · doi:10.1080/17461391.2019.1655098 · Cited by 124
“…shown that open-label placebos (i.e. overt administration of placebo) can significantly improve various conditions such as irritable bowel syndrome (Kaptchuk et al., 2010), lower back pain (Carvalho et al., 2016), allergic rhinitis (Schaefer, Harke, & Denke, 2016), depression (Kelley, Kaptchuk,…”
BackgroundManchikanti, L., Benyamin, R. M., Falco, F. J. E., Kaye, A. D., & Hirsch, J. A. (2014) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-014-3490-4 · Cited by 153
“The true definition of placebo is to inject an inactive substance into an inactive structure; for the purposes of this review, we have utilized an injection of placebo into the epidural space or over the nerve root by any approach as placebo [48, 49, 54, 82].”
BackgroundMethodPlacebo effect studies are susceptible to response bias and to other types of biases
Hróbjartsson, A., Kaptchuk, T. J., & Miller, F. G. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.01.008 · Cited by 150
“[41] Kaptchuk TJ, Friedlander E, Kelley JM, Sanchez MN, Kokkotou E,”
BackgroundSelf-citationFord, A. C., Wright-Hughes, A., Alderson, S. L., Ow, P.-L., Ridd, M. J., Foy, R., Bianco, G., Bishop, F. L., Chaddock, M., Cook, H., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01523-4 · Cited by 146
“52,53 Other possible explanations include provision of the British Dietetic Association dietary advice sheet to all participants, regular follow-up, usual general practitioner care throughout, and telephone calls from a research nurse to assist with dose titration and trial medication reissue.”
Open-Label Placebo Treatment for Cancer-Related Fatigue: A Randomized-Controlled Clinical Trial
Hoenemeyer, T. W., Kaptchuk, T. J., Mehta, T. S., & Fontaine, K. R. (2018) · Scientific Reports · doi:10.1038/s41598-018-20993-y · Cited by 148
Self-citationPlacebo effect of medication cost in Parkinson disease: A randomized double-blind study
Espay, A. J., Norris, M. M., Eliassen, J. C., Dwivedi, A., Smith, M. S., Banks, C., Allendorfer, J. B., Lang, A. E., Fleck, D. E., Linke, M. J., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001282 · Cited by 145
“Given that the benevolent use of deception to generate a placebo response is in conflict with the principle of respect for patient autonomy, preliminary data suggest that the use of “nonblind placebo” (inert content disclosed) may be effective(36) and eliminate the need for deception or concealment even in a randomize…”
BackgroundDamien, J., Colloca, L., Belleï-Rodriguez, C.-É., & Marchand, S. (2018) · International review of neurobiology · doi:10.1016/bs.irn.2018.07.024 · Cited by 167
“…of symptoms and pain relief) in comparison to the absence of treatment across many clinical conditions: irritable bowel syndrome, depression, allergic rhinitis, back pain, and attention deficit hyperactivity disorder (Charlesworth et al., 2017; Colloca & Howick, 2018; Kaptchuk et al., 2010).”
BackgroundOpen label placebo: can honestly prescribed placebos evoke meaningful therapeutic benefits?
Kaptchuk, T. J., & Miller, F. G. (2018) · BMJ · doi:10.1136/bmj.k3889 · Cited by 137
Self-citationManchikanti, L., Gharibo, C. G., Gilligan, C. J., Hirsch, J. A., Nampiaparampil, D. E., Manchikanti, K. N., Falco, F. J. E., Singh, V. P., Benyamin, R. M., Kaye, A., et al. (2015) · Surgical Neurology International · doi:10.4103/2152-7806.156598 · Cited by 136
“[65,70,71,74,84,85,103] And thus far, appropriately designed placebo studies (injecting inactive solutions into inactive structures) have not resulted in a significant placebo effect.”
BackgroundCox, S. R., Prince, A. C., Myers, C. E., Irving, P. M., Lindsay, J. O., Lomer, M. C., & Whelan, K. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx073 · Cited by 133
Howe, L. C., Leibowitz, K. A., & Crum, A. J. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00475 · Cited by 165
Ljótsson, B., Andersson, G., Andersson, E., Hedman, E., Lindfors, P., Andréewitch, S., Rück, C., & Lindefors, N. (2011) · BMC Gastroenterology · doi:10.1186/1471-230x-11-110 · Cited by 132
“Several trials of psychological treatments for IBS have failed to show differential effects on symptoms when using attention control conditions [32,62-64], and a recent study showed that IBS patients even respond to open-label placebo [65].”
BackgroundEfficacy of Epidural Injections in Managing Chronic Spinal Pain: A Best Evidence Synthesis
Kaye, A. D., Manchikanti, L., Abdi, S., Atluri, S., Bakshi, S., Benyamin, R., Boswell, M. V., Buenaventura, R., Candido, K. D., Cordner, H. J., et al. (2015) · Pain Physician · doi:10.36076/ppj.2015/18/e939 · Cited by 149
“The magnitude of placebo effects (250) and nocebo effects (251,252), patient-clinician communication, and therapeutic outcomes (252), avoidance of nocebo effects to optimize treatment outcome (253), lack of differences between treatment and placebo effects (254), placebos without deception (255), and placebo use in cl…”
BackgroundAre open‐Label Placebos Ethical? Informed Consent and Ethical Equivocations
Blease, C., Colloca, L., & Kaptchuk, T. J. (2016) · Bioethics · doi:10.1111/bioe.12245 · Cited by 129
Self-citationSimopoulos, T. T. (2015) · Pain Physician · doi:10.36076/ppj.2015/18/e713 · Cited by 131
Harnessing the placebo effect: the need for translational research
Colloca, L., & Miller, F. G. (2011) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2010.0399 · Cited by 125
Self-citationManchikanti, L., Kaye, A. D., Manchikanti, K. N., Boswell, M. V., Pampati, V., & Hirsch, J. A. (2015) · Anesthesiology and Pain Medicine · doi:10.5812/aapm.23139 · Cited by 129
“For this review, we considered an injection of a placebo into the epidural space or over the nerve root by any approach as a placebo, even though it is an impure placebo (60-62).”
MethodSchaefer, M., Sahin, T., & Berstecher, B. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192758 · Cited by 136
“While there is an increasing body of evidence that open-label placebos are effective for improving symptoms [8–14], it still remains unclear how placebos without deception might influence patients.”
InfluentialThe Role of Patient–Practitioner Relationships in Placebo and Nocebo Phenomena
Blasini, M., Peiris, N., Wright, T., & Colloca, L. (2018) · International Review of Neurobiology · doi:10.1016/bs.irn.2018.07.033 · Cited by 121
“…with deception, newer research has found that placebo effects can occur even when an individual is aware of receiving or having received a placebo intervention (Ballou et al., 2017; Carvalho et al., 2016; Colloca, Pine, Ernst, Miller, & Grillon, 2016; Kaptchuk et al., 2010; Locher et al., 2017).”
BackgroundInfluentialKleine-Borgmann, J., Schmidt, K., Hellmann, A., & Bingel, U. (2019) · Pain · doi:10.1097/j.pain.0000000000001683 · Cited by 121
Complementary and alternative medicines in irritable bowel syndrome: An integrative view
Grundmann, O. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i2.346 · Cited by 120
Alfonsson, S., Olsson, E., & Hursti, T. (2016) · Journal of Medical Internet Research · doi:10.2196/jmir.5352 · Cited by 118
“Finally, patients’ belief in a treatment may have a very strong effect on the outcome as seen in studies on placebo effects [31].”
Conditioned Placebo Analgesia Persists When Subjects Know They Are Receiving a Placebo
Schafer, S. M., Colloca, L., & Wager, T. D. (2015) · The Journal of Pain · doi:10.1016/j.jpain.2014.12.008 · Cited by 117
“allow placebos to serve as either dose extenders for chemically active treatments(28,29) or effective treatments on their own.(17) However, expectancy theory is challenged by demonstrations that placebo treatments can result in analgesia even when participants are unaware they are receiving a treatment.”
BackgroundResultManchikanti, L., Cash, K. A., Pampati, V., & Falco, F. J. E. (2014) · Pain Physician · doi:10.36076/ppj.2014/17/e489 · Cited by 136
The influence of personality traits on the placebo/nocebo response
Kern, A., Kramm, C., Witt, C. M., & Barth, J. (2020) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2019.109866 · Cited by 117
Peciña, M., Sikora, M., Avery, E. T., Heffernan, J., Peciña, S., Mickey, B. J., & Zubieta, J.-K. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.08.427 · Cited by 115
“While open-label placebos have been associated with symptom relief under expectations of improvement (Kaptchuk et al., 2010), and could potentially lead to changes in DA neurotransmission, this has not been the case when placebos are administered in the absence of such expectations, and therefore…”
Patients' attitudes about the use of placebo treatments: telephone survey
Hull, S. C., Colloca, L., Avins, A. L., Gordon, N. P., Somkin, C. P., Kaptchuk, T. J., & Miller, F. G. (2013) · BMJ · doi:10.1136/bmj.f3757 · Cited by 108
Self-citationPlacebos Without Deception: Outcomes, Mechanisms, and Ethics
Colloca, L., & Howick, J. (2018) · International Review of Neurobiology · doi:10.1016/bs.irn.2018.01.005 · Cited by 108
“In spite of the lack of intuitive appeal, numerous studies have demonstrated that deception may not be needed to elicit placebo effects and have also demonstrated potential effectiveness at improving significant clinical outcomes in patients with irritable bowel syndrome (IBS) (Kaptchuk et al., 2010), chronic low back…”
BackgroundMethodInfluentialDougherty, M. R., Hamovitz, T., & Tidwell, J. W. (2016) · Psychonomic Bulletin & Review · doi:10.3758/s13423-015-0865-9 · Cited by 112
Botulinum toxin type A for neuropathic pain in patients with spinal cord injury
Han, Z., Song, D. H., Oh, H. M., & Chung, M. E. (2016) · Annals of Neurology · doi:10.1002/ana.24605 · Cited by 117
Open-Label Placebos Improve Symptoms in Allergic Rhinitis: A Randomized Controlled Trial
Schaefer, M., Harke, R., & Denke, C. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447242 · Cited by 106
Rethinking Explicit Expectations: Connecting Placebos, Social Cognition, and Contextual Perception
Schwarz, K. A., Pfister, R., & Büchel, C. (2016) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2016.04.001 · Cited by 127
Placebo manipulations reduce hyperalgesia in neuropathic pain
Petersen, G. L., Finnerup, N. B., Nørskov, K. N., Grosen, K., Pilegaard, H. K., Benedetti, F., Price, D. D., Jensen, T. S., & Vase, L. (2012) · Pain · doi:10.1016/j.pain.2012.03.011 · Cited by 105
Schmid, J., Theysohn, N., Ga, F., Benson, S., Gramsch, C., Forsting, M., Gizewski, E. R., & Elsenbruch, S. (2013) · Pain · doi:10.1016/j.pain.2013.07.013 · Cited by 102
“First, chronic abdominal pain, such as in IBS, is highly prevalent, with detrimental individual and socioeconomic impact [45] and limited effective treatment options.”
BackgroundInfluentialOpen-label placebo vs double-blind placebo for irritable bowel syndrome: a randomized clinical trial
Lembo, A. J., Kelley, J. M., Nee, J. W., Ballou, S., Iturrino, J., Cheng, V., Rangan, V., Katon, J. M., Hirsch, W., Kirsch, I., et al. (2021) · Pain · doi:10.1097/j.pain.0000000000002234 · Cited by 111
“In 2010, we reported a pilot randomized controlled trial (RCT) of nonconcealed, “open-label” placebos (OLPs) as treatment for irritable bowel syndrome (IBS) that challenged this conventional belief.(17) The study showed that participants receiving OLP reported greater improvement in IBS”
BackgroundResultSelf-citationElsenbruch, S., Kotsis, V., Benson, S., Rosenberger, C., Reidick, D., Schedlowski, M., Bingel, U., Theysohn, N., Forsting, M., & Gizewski, E. R. (2012) · Pain · doi:10.1016/j.pain.2011.10.036 · Cited by 99
“S. Elsenbruch et al. / PAIN 153 (2012) 382–390 383 been conducted within patients with IBS [23,30], but thus far no knowledge regarding the neural mechanisms of visceral placebo analgesia for rectal pain exists in healthy subjects.”
BackgroundInfluentialThe Placebo and Nocebo Phenomena: Their Clinical Management and Impact on Treatment Outcomes
Chavarria, V., Vian, J., Pereira, C. L., Data-Franco, J., Fernandes, B. S., Berk, M., & Dodd, S. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.01.031 · Cited by 136
“In a study of IBS, patients were informed they were being treated with placebo and still developed a positive clinical response.(51) A partial reinforcement paradigm, placebo-controlled drug reduction (PCDR) (use of a full dose of medication for a set period of time [acquisition period] followed by a maintenance or ev…”
Petersen, G. L., Finnerup, N. B., Grosen, K., Pilegaard, H. K., Tracey, I., Benedetti, F., Price, D. D., Jensen, T. S., & Vase, L. (2014) · Pain · doi:10.1016/j.pain.2014.09.036 · Cited by 97
“The investigator took time to establish a good patient– practitioner relationship [27,30], and the patient’s medical history and detailed descriptions of the patient’s development of pain were obtained.”
Miller, F. G., & Colloca, L. (2011) · Metamedicine · doi:10.1007/s11017-011-9179-8 · Cited by 111
“Some recent clinical trials aimed at understanding placebo responses have manipulated information disclosure and other elements of the treatment context, with results of potential relevance to improving patient care [13, 30, 31].”
BackgroundSelf-citationFaasse, K., Cundy, T., Gamble, G., & Petrie, K. J. (2013) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3182738826 · Cited by 96
“The power of expectations is such that benefit may be derived from open placebo treatment, which is presented as being effective at treating the patients’ condition (11).”
BackgroundBrim, R. L., & Miller, F. G. (2013) · Journal of Medical Ethics · doi:10.1136/medethics-2012-101045 · Cited by 91
Self-citationAllison, M. (2012) · Nature Biotechnology · doi:10.1038/nbt.2083 · Cited by 91
“In one striking study, nearly 60% of patients showed significant improvements in symptoms after taking a pill they knew to be a placebo 10 .”
BackgroundSystematic review and meta-analysis: Gastric electrical stimulation for gastroparesis
Levinthal, D. J., & Bielefeldt, K. (2016) · Autonomic Neuroscience · doi:10.1016/j.autneu.2016.03.004 · Cited by 96
“Yet, placebos could be exploited as risk-free therapeutic approaches for gastroparesis treatment, as has recently been shown in patients with irritable bowel syndrome (Kaptchuk et al., 2010).”
BackgroundManchikanti, L., Cash, K. A., McManus, C. D., Damron, K. S., Pampati, V., & Falco, F. J. E. (2015) · Pain Physician · doi:10.36076/ppj/2015.18.79 · Cited by 95
The PAC ‐ SYM questionnaire for chronic constipation: defining the minimal important difference
Yiannakou, Y., Tack, J. F., Piessevaux, H. H., Dubois, D., Quigley, E. M. M., Ke, M., Silva, S. D., Joseph, A., & Kerstens, R. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14349 · Cited by 92
“75) be considered in placebo-controlled clinical trials of chronic constipation, because the placebo response is known to be high in patients with bowel disorders.(35) Estimates of the MID were similar when data from each of the six clinical trials conducted across different locations throughout the world were analyse…”
ResultProbiotics for human health –new innovations and emerging trends
Grover, S., Rashmi, H. M., Srivastava, A. K., & Batish, V. K. (2012) · Gut Pathogens · doi:10.1186/1757-4749-4-15 · Cited by 87
“Dr Ander apprised the delegates that Probiotic strains have been used in several clinical studies [33,34] on subjects with GI symptoms and further conveyed that the outcome of such studies suggest that certain probiotic strains alleviate specific symptoms, particularly bloating/ distension, abdominal pain and constipa…”
BackgroundFord, A. C., & Talley, N. J. (2012) · BMJ · doi:10.1136/bmj.e5836 · Cited by 84
Manaï, M., van Middendorp, H., Veldhuijzen, D. S., Huizinga, T. W. J., & Evers, A. W. M. (2019) · PAIN Reports · doi:10.1097/pr9.0000000000000699 · Cited by 91
“growing body of literature is focusing on how the positive effects that can be reached by using placebo effects can be optimized for use in clinical practice.(2,39,58,102,103) Much less attention has been paid to the question on how to prevent, minimize, or extinguish negative expectations by means of the nocebo effec…”
BackgroundPavlovian Conditioning of Immunological and Neuroendocrine Functions
Hadamitzky, M., Lückemann, L., Pacheco-López, G., & Schedlowski, M. (2020) · Physiological Reviews · doi:10.1152/physrev.00033.2018 · Cited by 84
Stevenson, C., Blaauw, R., Fredericks, E., Visser, J., & Roux, S. (2014) · Nutrition · doi:10.1016/j.nut.2014.02.010 · Cited by 92
“Results from one RCT demonstrated that even placebos administered openly were an effective treatment for patients with IBS [33].”
BackgroundManchikanti, L., Cash, K. A., McManus, C. D., Pampati, V., & Benyamin, R. M. (2013) · Pain Physician · doi:10.36076/ppj.2013/16/e494 · Cited by 85
Linde, K., Atmann, O., Meißner, K., Schneider, A., Meister, R., Kriston, L., & Werner, C. (2018) · PLoS ONE · doi:10.1371/journal.pone.0202211 · Cited by 98
“Currently, there is considerable interest in the prescription of (pure) placebos without deception (sometimes referred to as “open-label placebo” [46]).”
BackgroundSchafer, S. M., Geuter, S., & Wager, T. D. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.10.008 · Cited by 85
“However, placebo effects induced via this process do not require explicit cognitive control, nor are they be immediately affected by new information. the treatment is chemically inert (Kam-Hansen et al., 2014; Kaptchuk et al., 2010).”
InfluentialLoeser, J. D. (2012) · The Clinical Journal of Pain · doi:10.1097/ajp.0b013e318230f6c1 · Cited by 78
An update on non-pharmacological interventions for pain relief
Wang, Y., Aaron, R. V., Attal, N., & Colloca, L. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.101940 · Cited by 130
“59 Similarly, research by Car-valho et al. demonstrated that OLPs provided significant relief for chronic lower back pain compared to standard treatment.”
Open-label placebo reduces fatigue in cancer survivors: a randomized trial
Zhou, E. S., Hall, K. T., Michaud, A. L., Blackmon, J. E., Partridge, A. H., & Recklitis, C. J. (2018) · Supportive Care in Cancer · doi:10.1007/s00520-018-4477-6 · Cited by 84
Placebos without deception reduce self-report and neural measures of emotional distress
Guevarra, D. A., Moser, J. S., Wager, T. D., & Kross, E. F. (2020) · Nature Communications · doi:10.1038/s41467-020-17654-y · Cited by 79
The relativity of ‘placebos’: defending a modified version of Grünbaum’s definition
Howick, J. (2016) · Synthese · doi:10.1007/s11229-015-1001-0 · Cited by 86
A Review of the Theoretical and Biological Understanding of the Nocebo and Placebo Phenomena
Dodd, S., Dean, O. M., Vian, J., & Berk, M. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.01.010 · Cited by 88
“Participants in the placebo-treated group had significantly higher global improvement scores.(10) In this study, the placebo effect occurred even though the participants were told they would be receiving an inert substance “like sugar pills.”
BackgroundBrain‐Gut Axis: From Basic Understanding to Treatment of IBS and Related Disorders
Camilleri, M., & Lorenzo, C. D. (2012) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e31823d34c3 · Cited by 82
“Placebos administered without deception also may be effective in the treatment of IBS (61).”
Background
Metadata
- Authors
- Kaptchuk, T. J., Friedlander, E., Kelley, J. M., Sanchez, M. N., Kokkotou, E., Singer, J. P., Kowalczykowski, M., Miller, F. G., Kirsch, I., & Lembo, A. J.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- National Institutes of Health (US)
- University of Hull (GB)
- Corresponding author
- Kaptchuk, Ted J.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-12-22
- Volume
- 5
- Issue
- 12
- Pages
- e15591
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3008733
- OpenAlex
- W2105330971
- Semantic Scholar
- 3d8aac4fba0e556c2d0898ad83cd3df11576e90c
- Cited by
- 900
- References
- 43
- Citations by year
- 2026: 28 · 2025: 44 · 2024: 48 · 2023: 56 · 2022: 55 · 2021: 67 · 2020: 72 · 2019: 55 · 2018: 97 · 2017: 48 · 2016: 55 · 2015: 55 · 2014: 65 · 2013: 48 · 2012: 58
- FWCI
- 29.43
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- U.S. Department of Health and Human Services
- Bernard Osher Foundation
- National Institutes of Health (5r01at000402-04)
- Japan Society for the Promotion of Science (13J11021)
- National Center for Complementary and Alternative Medicine
- National Center for Complementary and Integrative Health (R01AT004662, K24AT004095, R01 AT00402-01)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Complementary and alternative medicine › Acupuncture Treatment Research Studies
- Keywords
- irritable bowel syndrome, placebo effect, open-label placebo, symptom severity, quality of life, patient-provider interaction, informed consent
- MeSH terms
- Adult, Female, Humans, Deception, Male, Middle Aged, Placebos, Time Factors, Treatment Outcome, Patient Satisfaction, Irritable Bowel Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

